Search
Benchtalk 2025: Generate:Biomedicines' VP of Informatics Stephen Kottmann describes the investments in technology that ensures only the highest quality data returns back into its models
He walks us through the design, build, test, learn model that is the foundation of Generate's approach to drug development. Coverage brought to you by
Oct 14
HumanX: Generate Biomedicines' CEO Mike Nally describes how he sees AI going from improvements in optimization to drugging the undruggable
From the big HumanX AI conference in Las Vegas, he describes the overall path he sees AI taking in its contributions to drug development,...
Mar 13
AI x Bio Summit: Generate Biomedicines' CEO Mike Nally gives an update on the company's clinical and emerging programs
He describes clinical programs targeting COVID and TSLP, as well as emerging programs in the ADC space, TL1A, IL13, and more.
Jul 25, 2024
Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development
Mike Nally describes Generate's near term programs how he sees computational advances changing where the field is headed over the long term.
Sep 18, 2023
AI in biotech with Generate Biomedicines’ Mike Nally
Generate Biomedicine's Mike Nally describes how AI might impact biotech in the future at #JPM23.
Jan 11, 2023
.png){kind=logo}
